Expanding the Use of Ivosidenib (Tibsovo) In Newly Approved Combination For IDH1-Mutated AML with Eytan Stein, MD, Memorial Sloan Kettering
Expanding the Use of Ivosidenib (Tibsovo) In Newly Approved Combination For IDH1-Mutated AML with Eytan Stein, MD, Memorial Sloan Kettering image
Aug 24, 2022 / 11:00AM - 12:00PM EDT
HealthTree Podcast for AML
videocam
Can't make it to the event?
We send a recording to all registered participants of the event!

Event Description

IF YOU WOULD PREFER TO JOIN THE SHOW BY PHONE, PLEASE CALL (515) 602-9728

*You need to join by phone if you want to ask Dr. Stein your questions.*

IDH mutations are found in approximately 20% of adults with AML. Both IDH1 and IDH2 mutations are typically found in older AML patients and have an intermediate risk profile, with IDH2 being the more common of the two. Targeted therapy drugs, called IDH inhibitors have been developed to address these mutations.

Ivosidenib (Tibsovo) and enasidinib (Idhifa) are IDH inhibitors and were approved for use in relapsed/refractory AML with IDH1 and IDH2 mutations, respectively. Clinical trials have been exploring the use of different combinations with other drugs such as azacitidine and venetoclax to improve their effectiveness. 

Ivosidenib (Tibsovo) was just recently approved by the FDA in May 2022 for use in combination with azacitidine for newly diagnosed patients age 75 years or older and those not able to do intensive chemotherapy.

In this podcast episode, Dr. Eytan Stein will discuss IDH mutations, the current treatment options, as well as the recent FDA approval of ivosidenib (Tibsovo) and what that means for today's treament landscape.

Thank you to our episode sponsor, Bristol Myers Squibb.

Schedule & Agenda

The panelist Kerith Amen
Welcome
11:00AM
Kerith Amen
Welcome, Announcements & Introduction
The panelist Eytan Stein, MD
Interview
11:05AM
Eytan Stein, MD
Dr. Stein will discuss IDH mutations in AML and the current treatment options available, as well as the recent FDA approval of the use of ivosidenib (Tibsovo) in combination with azacitidine.
The panelist Audience
Q&A
11:50AM
Audience
Audience is able to call in to the radio show, (515) 602-9728, to ask Dr. Stein questions about what was discussed during our interview today.

Speakers & Moderators

The panelist Kerith Amen
Kerith Amen
New Orleans, Louisiana

Kerith joined HealthTree Foundation as a Community Co-Director for AML in 2022. She is a mother to a spirited eight-year-old daughter, Adair, and their beloved rescue, Violet. She lost her best friend and husband, Rob, to AML in March 2018. Kerith wishes she had a resource such as HealthTree for AML during Rob’s illness. She is a strong supporter of HealthTree's mission. She hopes that by sharing her experience, she may help other patients and caregivers navigate an AML diagnosis.

Read Bio
The panelist Eytan Stein, MD
Eytan Stein, MD
New York, New York

Hematologist Oncologist, Director of the Program for Drug Development in Leukemia at MSKCC

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

(800) 930-5159

email

Support@healthtree.org

Get the latest thought leadership on AML delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for AML Newsletter" for AML news, life with AML stories, AML clinical trials, AML 101 articles and events with AML experts.

Thanks to our HealthTree Community for AML Sponsors:

Jazz Pharmaceuticals
AbbVie
Amgen
Genentech
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube

 

Terms of Use and Privacy Policy     Newsroom     About    Donations    Find an AML Specialist     Newsletter     Learn     Connect

 

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / HealthTree for AML is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

https://www.guidestar.org/profile/45-5354811